rs121909569 — SERPINC1 Ser148Pro

SERPINC1 Ser148Pro — Antithrombin's Gatekeeper Compromised

Antithrombin — encoded by SERPINC1 on chromosome 1 — is the principal brake on coagulation. It is a serpin¹¹ serpin
serine protease inhibitor: a family of proteins that regulate coagulation, fibrinolysis, and inflammation by acting as decoy substrates for serine proteases that permanently inactivates thrombin and Factor Xa, the two enzymes most responsible for generating fibrin clot. Without functional antithrombin, coagulation runs unchecked at the slightest provocation. The Ser148Pro variant (rs121909569) in SERPINC1 substitutes proline for serine at position 148, altering the protein's conformation in a way that impairs both its heparin-binding capacity and its reactive site — a dual defect that defines type II pleiotropic effect (type II-PE) antithrombin deficiency²² type II pleiotropic effect (type II-PE) antithrombin deficiency
The most clinically severe subtype: type I reduces antigen and activity equally; type II-HBS reduces heparin binding only; type II-PE reduces both heparin-dependent and heparin-independent anticoagulant activity.

The Mechanism

Antithrombin inhibits its target proteases through a conformational mechanism called the serpin suicide substrate pathway. The reactive site loop — the region that presents itself as a decoy peptide to thrombin and Factor Xa — must be positioned correctly, and heparin binding dramatically accelerates the inhibitory reaction by bridging antithrombin to its targets. The Ser148Pro substitution introduces a proline residue into a region of the protein that connects the heparin-binding domain to the reactive site loop. Proline is conformationally rigid — it eliminates a peptide bond rotational degree of freedom that other amino acids allow — and its insertion at position 148 disrupts the transmission of the conformational change that heparin binding normally induces. The result is impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency³³ impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency
Pleiotropic effect classification: affects both the heparin-binding arm and the reactive site — the two mechanisms by which antithrombin inactivates thrombin and Factor Xa. Plasma antithrombin activity and antigen levels typically fall to 40–60% of normal in heterozygous carriers, leaving half the normal coagulation brake.

Homozygous antithrombin deficiency has not been reported in viable offspring, suggesting complete absence of antithrombin activity is incompatible with survival — underscoring how essential this protein is to basic hemostasis.

The Evidence

A 2024 systematic review and meta-analysis by Alnor et al.⁴⁴ 2024 systematic review and meta-analysis by Alnor et al.
39167180: Anne Alnor, Annals of Hematology — pooled data across multiple cohort studies of hereditary thrombophilia placed antithrombin deficiency at an odds ratio of 4.01 (95% CI 2.50–6.44) for venous thromboembolism — intermediate between homozygous Factor V Leiden (OR 5.58) and heterozygous Factor V Leiden (OR 2.97). This positions AT deficiency as a high-impact inherited thrombophilia, albeit with wide confidence intervals reflecting the rarity of prospective cohort data.

A review of hereditary antithrombin deficiency treatment⁵⁵ review of hereditary antithrombin deficiency treatment
Rodgers GM, Thromb Haemost 2009 synthesized earlier cohort data and estimated a ≥50% lifetime risk of VTE in confirmed AT-deficient individuals — three to seven times higher than the residual risk associated with other thrombophilias such as protein C or protein S deficiency. Antithrombin levels in heterozygous carriers typically run at 40–60% of normal — an unusually severe haploinsufficiency for a dominant variant.

The pregnancy-specific risk is particularly elevated⁶⁶ particularly elevated
Croles et al. BMJ 2017 Bayesian meta-analysis; RCT-level data are unavailable for ethical reasons, so Bayesian modeling of observational studies provides the best evidence: antithrombin deficiency carries an estimated 7.3% antepartum VTE risk (95% credible interval 1.8–15.6%) and 11.1% postpartum risk (3.7–21.0%). These absolute risks are among the highest of any inherited thrombophilia and drive the ACOG and ACCP recommendations for anticoagulant prophylaxis in affected pregnant women.

In a population-based cohort of 29,387 middle-aged Swedish adults⁷⁷ population-based cohort of 29,387 middle-aged Swedish adults
Manderstedt et al. JAHA 2022; Malmö Diet and Cancer cohort followed from 1991–2018, SERPINC1 disease-causing mutation carriers had a hazard ratio of 1.6 (95% CI 1.3–1.9) for incident VTE. This real-world unselected population estimate is lower than estimates from thrombophilia clinic cohorts (which select for symptomatic families), providing a more conservative but more generalizable risk figure.

Practical Actions

For heterozygous carriers of Ser148Pro, the clinical priorities are: documentation and disclosure (this result must be in medical records before any surgery, hospitalization, pregnancy, or hormonal therapy); thrombophilia specialist evaluation; and avoidance of high-risk provoking exposures. Routine (unprovoked) anticoagulation is not indicated for asymptomatic carriers, but high-risk situational prophylaxis during surgery, immobility, and pregnancy is strongly supported. Women considering combined hormonal contraceptives face multiplicative risk and should choose non-estrogen methods. Hematology consultation should precede any high-stakes decisions. First-degree relatives carry a 50% chance of inheriting the variant and benefit from cascade genetic testing before their first thrombotic event.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁸⁸ Factor V Leiden (rs6025, F5 R506Q)
The most common inherited thrombophilia, affecting ~5% of Europeans; compound heterozygosity with AT deficiency has been associated with much higher VTE risk than either alone. Double thrombophilia — inheriting both an antithrombin mutation and Factor V Leiden — produces additive or synergistic risk elevation. The prothrombin G20210A variant (rs1799963) represents a second compounding thrombophilic interaction. Any AT-deficient individual found to co-inherit one of these variants should have risk discussed by a hematologist as a combined clinical picture, not as two separate genetic findings.